Tel: 1-631-504-6093
Email:
Awesome Features1111

p53 target new drug! Aprea’s Blood Cancer Combination Therapy Receives FDA Breakthrough Therapy Designation

Aprea Therapeutics is a Boston-based biopharmaceutical company focused on developing and commercializing innovative cancer therapies that reactivate the tumor suppressor protein p53. Recently, the company announced that the U.S. food […]

Read More →

Novel Therapeutics in Acute Myeloid Leukemia

The disparity in clinical outcomes for patients with acute myeloid leukemia (AML) illustrates the heterogeneity of this disease. Overall survival (OS) in AML is impacted by many clinical, cytogenetic, and molecular factors. Although […]

Read More →